Tilray Brands
  • Tilray Brands (TLRY) has expanded its Good Supply cannabis brand portfolio
  • The brand’s latest product releases include larger packs of pre-rolls, new pre-roll strains, and new hash and milled flower products
  • Good Supply is one of Canada’s leading cannabis brands
  • Tilray Brands is a leading global cannabis-lifestyle and consumer packaged goods company
  • Tilray Stock (TSX:TLRY) opened trading at C$3.80

Tilray Brands (TLRY) has expanded its Good Supply cannabis brand portfolio and launched its latest flower campaign.

The brand’s latest product releases include larger packs of pre-rolls, new pre-roll strains, and new hash and milled flower products available in select provinces across Canada.

Good Supply’s latest product lineup includes:

  • Orange Frosting Flower: Available in Ontario only in 14g
  • Daily Grind Milled Flower: Available in Alberta in 30g and in Ontario, Manitoba and Saskatchewan in 14g
  • Party Pack Pre-Rolls: Available in Ontario, Alberta, Manitoba, and Saskatchewan
  • Watermelon Pre-rolls: Available for a limited time only in British Columbia, Manitoba and Saskatchewan as a 3×0.5g pre-roll offering
  • Temple Ball Hash: Available in Ontario, Alberta, Manitoba and Saskatchewan

Good Supply is one of Canada’s leading cannabis brands, available in flower, pre-rolls, vapes, and concentrates.

Tilray Brands is a cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.